|
1
|
Zhao K, Karimi A, Kelly L, Petre E, Marinelli B, Alexander ES, Sotirchos VS, Erinjeri JP, Covey A, Sofocleous CT, Harding JJ, Jarnagin W, Sigel C, Vakiani E, Ziv E, Yarmohammadi H. TP53 Mutation Predicts Worse Survival and Earlier Local Progression in Patients with Hepatocellular Carcinoma Treated with Transarterial Embolization. Curr Oncol 2025; 32:51. [PMID: 39851967 PMCID: PMC11764326 DOI: 10.3390/curroncol32010051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/02/2024] [Revised: 12/30/2024] [Accepted: 01/15/2025] [Indexed: 01/26/2025] Open
Abstract
The aim of this study was to evaluate associations between TP53 status and outcomes after transarterial embolization (TAE) for the treatment of patients with hepatocellular carcinoma (HCC). This single-institution study included patients from 1/2014 to 6/2022 who underwent TAE of HCC and genomic analysis of tumoral tissue. The primary outcome was overall survival (OS) with relation to TP53 status, and the secondary outcome was the time to progression. Survival analysis was performed using the Kaplan-Meier method. The time to progression with death or the last patient contact without progression as competing risks were used to obtain a cumulative incidence function, and the association with TP53 status was evaluated using the Gray test. In total, 75 patients (63 men) with a median age of 70.0 (IQR 62.0-76.3) years were included. Of these, 26/75 (34.7%) patients had TP53-mutant HCC. Patients with TP53-mutant HCC had a significantly worse median OS of 15.2 (95% CI, 9.5-29.3) months, versus 31.2 (95% CI, 21.2-52.4) months as the median OS (p = 0.023) for TP53 wild-type HCC. Competing risk analysis showed a shorter time to local hepatic progression (at the site of the previously treated tumor) after TAE in patients with TP53-mutant HCC. The cumulative incidences of local progression at 6 and 12 months for TP53-mutant HCC were 65.4% and 84.6%, versus 40.8% and 55.1% for TP53 wild-type HCC (p = 0.0072). A TP53 mutation may predict a worse overall survival and a shorter time to local progression in HCC patients treated with TAE.
Collapse
Affiliation(s)
- Ken Zhao
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Anita Karimi
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Luke Kelly
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Elena Petre
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Brett Marinelli
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Erica S. Alexander
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Vlasios S. Sotirchos
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Joseph P. Erinjeri
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Anne Covey
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Constantinos T. Sofocleous
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - James J. Harding
- Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
| | - William Jarnagin
- Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA;
| | - Carlie Sigel
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; (C.S.); (E.V.)
| | - Efsevia Vakiani
- Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA; (C.S.); (E.V.)
| | - Etay Ziv
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| | - Hooman Yarmohammadi
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA (E.P.); (B.M.); (E.S.A.); (V.S.S.); (J.P.E.); (A.C.); (C.T.S.); (E.Z.); (H.Y.)
| |
Collapse
|
|
2
|
Geevarghese R, Bodard S, Razakamanantsoa L, Marcelin C, Petre EN, Dohan A, Kastler A, Frandon J, Barral M, Soyer P, Cornelis FH. Interventional Oncology: 2024 Update. Can Assoc Radiol J 2024; 75:658-670. [PMID: 38444144 DOI: 10.1177/08465371241236152] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/07/2024] Open
Abstract
Interventional Oncology (IO) stands at the forefront of transformative cancer care, leveraging advanced imaging technologies and innovative interventions. This narrative review explores recent developments within IO, highlighting its potential impact facilitated by artificial intelligence (AI), personalized medicine and imaging innovations. The integration of AI in IO holds promise for accelerating tumour detection and characterization, guiding treatment strategies and refining predictive models. Imaging modalities, including functional MRI, PET and cone beam CT are reshaping imaging and precision. Navigation, fusion imaging, augmented reality and robotics have the potential to revolutionize procedural guidance and offer unparalleled accuracy. New developments are observed in embolization and ablative therapies. The pivotal role of genomics in treatment planning, targeted therapies and biomarkers for treatment response prediction underscore the personalization of IO. Quality of life assessment, minimizing side effects and long-term survivorship care emphasize patient-centred outcomes after IO treatment. The evolving landscape of IO training programs, simulation technologies and workforce competence ensures the field's adaptability. Despite barriers to adoption, synergy between interventional radiologists' proficiency and technological advancements hold promise in cancer care.
Collapse
Affiliation(s)
- Ruben Geevarghese
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Sylvain Bodard
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | | | - Clement Marcelin
- Department of Radiology, Bordeaux University, Hopital Pellegrin, Bordeaux, France
| | - Elena N Petre
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - Anthony Dohan
- Department of Radiology, Hopital Cochin, AP-HP, Paris, France
- Faculté de Médecine, Université Paris Cité, Paris, France
| | - Adrian Kastler
- Department of Radiology, Grenoble University Hospital, Grenoble, France
| | - Julien Frandon
- Department of Radiology, Nimes University Hospital, Nimes, France
| | - Matthias Barral
- Department of Radiology, Sorbonne University, Hopital Tenon, Paris, France
| | - Philippe Soyer
- Department of Radiology, Hopital Cochin, AP-HP, Paris, France
- Faculté de Médecine, Université Paris Cité, Paris, France
| | - François H Cornelis
- Department of Radiology, Memorial Sloan Kettering Cancer Center, New York, NY, USA
- Department of Radiology, Sorbonne University, Hopital Tenon, Paris, France
- Weill Cornell Medical College, New York, NY, USA
| |
Collapse
|